Can primary care team-based transition to insulin improve outcomes in adults with type 2 diabetes: the stepping up to insulin cluster randomized controlled trial protocol

被引:14
|
作者
Furler, John S. [1 ]
Young, Doris [1 ]
Best, James [2 ]
Patterson, Elizabeth [3 ]
O'Neal, David [4 ]
Liew, Danny [5 ]
Speight, Jane [6 ,7 ,8 ]
Segal, Leonie [9 ]
May, Carl [10 ]
Manski-Nankervis, Jo-Anne [1 ]
Holmes-Truscott, Elizabeth [6 ,7 ]
Ginnivan, Louise [1 ]
Blackberry, Irene D. [1 ]
机构
[1] Univ Melbourne, Gen Practice & Primary Healthcare Acad Ctr, Carlton, Vic 3053, Australia
[2] Univ Melbourne, Sch Med, Parkville, Vic 3052, Australia
[3] Univ Melbourne, Sch Nursing, Parkville, Vic 3052, Australia
[4] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia
[5] Univ Melbourne, Royal Melbourne Hosp, Melbourne EpiCtr, Parkville, Vic 3050, Australia
[6] Australian Ctr Behav Res Diabet, Melbourne, Vic, Australia
[7] Deakin Univ, Ctr Mental Hlth & Wellbeing Res, Sch Psychol, Burwood, Vic, Australia
[8] AHP Res, Hornchurch, Essex, England
[9] Univ S Australia, Sch Populat Hlth, Div Hlth Sci, Adelaide, SA 5000, Australia
[10] Univ Southampton, Fac Hlth Sci, Southampton SO17 1BJ, Hants, England
来源
IMPLEMENTATION SCIENCE | 2014年 / 9卷
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
Type; 2; diabetes; Primary care; Nursing; Randomized trial; Insulin; Implementation; Australia; Health services research; GLYCEMIC CONTROL; CLINICAL INERTIA; THERAPY; INITIATION; MANAGEMENT; RESISTANCE; HYPERGLYCEMIA; STATEMENT; COMMUNITY; METFORMIN;
D O I
10.1186/1748-5908-9-20
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Type 2 diabetes (T2D) brings significant human and healthcare costs. Its progressive nature means achieving normoglycaemia is increasingly difficult, yet critical to avoiding long term vascular complications. Nearly one-half of people with T2D have glycaemic levels out of target. Insulin is effective in achieving glycaemic targets, yet initiation of insulin is often delayed, particularly in primary care. Given limited access to specialist resources and the size of the diabetes epidemic, primary care is where insulin initiation must become part of routine practice. This would also support integrated holistic care for people with diabetes. Our Stepping Up Program is based on a general practitioner (GP) and practice nurse (PN) model of care supported appropriately by endocrinologists and credentialed diabetes educator-registered nurses. Pilot work suggests the model facilitates integration of the technical work of insulin initiation within ongoing generalist care. Methods: This protocol is for a cluster randomized controlled trial to examine the effectiveness of the Stepping Up Program to enhance the role of the GP-PN team in initiating insulin and improving glycaemic outcomes for people with T2D. 224 patients between the ages of 18 and 80 years with T2D, on two or more oral hypoglycaemic agents and with an HbA1c >= 7.5% in the last six months will be recruited from 74 general practices. The unit of randomization is the practice. Primary outcome is change in glycated haemoglobin HbA1c (measured as a continuous variable). We hypothesize that the intervention arm will achieve an absolute HbA1c mean difference of 0.5% lower than control group at 12 months follow up. Secondary outcomes include the number of participants who successfully transfer to insulin and the proportion who achieve HbA1c measurement of <7.0%. We will also collect data on patient psychosocial outcomes and healthcare utilization and costs. Discussion: The study is a pragmatic translational study with important potential implications for people with T2D, healthcare professionals and funders of healthcare though making better use of scarce healthcare resources, improving timely access to therapy that can improve disease outcomes.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] A pragmatic randomized clinical trial of insulin glargine 300 U/mLvs first-generation basal insulin analogues in insulin-naive adults with type 2 diabetes: 6-month outcomes of theACHIEVEControl study
    Meneghini, Luigi F.
    Sullivan, Sean D.
    Oster, Gerry
    Busch, Robert
    Cali, Anna M. G.
    Dauchy, Arnaud
    Gill, Jasvinder
    Bailey, Timothy S.
    DIABETES OBESITY & METABOLISM, 2020, 22 (11) : 2004 - 2012
  • [42] Will Mobile Diabetes Education Teams (MDETs) in primary care improve patient care processes and health outcomes? Study protocol for a randomized controlled trial
    Gucciardi, Enza
    Fortugno, Mariella
    Horodezny, Stacey
    Lou, Wendy
    Sidani, Souraya
    Espin, Sherry
    Webster, Fiona
    Shah, Baiju R.
    TRIALS, 2012, 13
  • [43] Will Mobile Diabetes Education Teams (MDETs) in primary care improve patient care processes and health outcomes? Study protocol for a randomized controlled trial
    Enza Gucciardi
    Mariella Fortugno
    Stacey Horodezny
    Wendy Lou
    Souraya Sidani
    Sherry Espin
    Fiona Webster
    Baiju R Shah
    Trials, 13
  • [44] Development of an information system and mobile application for the care of type 2 diabetes patients at the primary care level for the health sector in Mexico: study protocol for a randomized controlled, open-label trial
    Barengo, Noel C.
    Manuel Apolinar, Leticia
    Estrada Cruz, Norma A.
    Fernandez Garate, Jose E.
    Correa Gonzalez, Roberto A.
    Diaz Valencia, Paula A.
    Cinco Gonzalez, Cecilia Alicia
    Gomez Rodriguez, Jose Alberto
    Cisneros Gonzalez, Nelly
    TRIALS, 2022, 23 (01)
  • [45] Effectiveness of the EMPOWER-PAR Intervention in Improving Clinical Outcomes of Type 2 Diabetes Mellitus in Primary Care: A Pragmatic Cluster Randomised Controlled Trial
    Ramli, Anis Safura
    Selvarajah, Sharmini
    Daud, Maryam Hannah
    Haniff, Jamaiyah
    Abdul-Razak, Suraya
    Tg-Abu-Bakar-Sidik, Tg Mohd Ikhwan
    Bujang, Mohamad Adam
    Chew, Boon How
    Rahman, Thuhairah
    Tong, Seng Fah
    Shafie, Asrul Akmal
    Lee, Verna K. M.
    Ng, Kien Keat
    Ariffin, Farnaza
    Abdul-Hamid, Hasidah
    Mazapuspavina, Md Yasin
    Mat-Nasir, Nafiza
    Chan, Chun W.
    Yong-Rafidah, Abdul Rahman
    Ismail, Mastura
    Lakshmanan, Sharmila
    Low, Wilson H. H.
    BMC FAMILY PRACTICE, 2016, 17 : 1 - 18
  • [46] New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
    Bolli, G. B.
    Riddle, M. C.
    Bergenstal, R. M.
    Ziemen, M.
    Sestakauskas, K.
    Goyeau, H.
    Home, P. D.
    DIABETES OBESITY & METABOLISM, 2015, 17 (04) : 386 - 394
  • [47] Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)
    Rosenstock, J.
    Hollander, P.
    Bhargava, A.
    Ilag, L. L.
    Pollom, R. K.
    Zielonka, J. S.
    Huster, W. J.
    Prince, M. J.
    DIABETES OBESITY & METABOLISM, 2015, 17 (08) : 734 - 741
  • [48] Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape)
    Vora, J.
    Cohen, N.
    Evans, M.
    Hockey, A.
    Speight, J.
    Whately-Smith, C.
    DIABETES OBESITY & METABOLISM, 2015, 17 (12) : 1133 - 1141
  • [49] Implementation of an Oral Care Protocol for Primary Diabetes Care: A Pilot Cluster-Randomized Controlled Trial
    Verhulst, Martijn J. L.
    Teeuw, Wijnand J.
    Gerdes, Victor E. A.
    Loos, Bruno G.
    ANNALS OF FAMILY MEDICINE, 2021, 19 (03) : 197 - 206
  • [50] Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial
    Onishi, Yukiko
    Iwamoto, Yasuhiko
    Yoo, Soon Jib
    Clauson, Per
    Tamer, Soren C.
    Park, Sungwoo
    JOURNAL OF DIABETES INVESTIGATION, 2013, 4 (06) : 605 - 612